Not available
Quote | Intra-Cellular Therapies Inc. (NASDAQ:ITCI)
Last: | $69.07 |
---|---|
Change Percent: | 0.77% |
Open: | $67.81 |
Close: | $68.54 |
High: | $69.13 |
Low: | $67.68 |
Volume: | 598,759 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Intra-Cellular Therapies Inc. (NASDAQ:ITCI)
2024-06-20 15:00:05 ET Graig Suvannavejh from Mizuho Securities issued a price target of $100.00 for ITCI on 2024-06-20 12:10:00. The adjusted price target was set to $100.00. At the time of the announcement, ITCI was trading at $76.06. The overall price target consensus...
2024-06-19 02:08:12 ET Summary Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. I...
Message Board Posts | Intra-Cellular Therapies Inc. (NASDAQ:ITCI)
Subject | By | Source | When |
---|---|---|---|
Geez..... No posting on this stock for over | Chrisny73 | investorshub | 12/22/2021 9:28:10 PM |
$ITCI > diluting > shelf placement last Friday! | crudeoil24 | investorshub | 09/14/2020 5:32:46 PM |
$ITCI respecting the ma20 on the 240min chart ~ | $treet $inatra | investorshub | 09/14/2020 5:27:21 PM |
znewcar1: ITCI 72% v43,9M c31.86 f67,3M gap up preMH42.99 S28.5 | znewcar1 | investorshangout | 09/09/2020 9:09:29 PM |
* * $ITCI Video Chart 09-09-2020 * * | ClayTrader | investorshub | 09/09/2020 8:37:57 PM |
News, Short Squeeze, Breakout and More Instantly...
Intra-Cellular Therapies Inc. Company Name:
ITCI Stock Symbol:
NASDAQ Market:
Intra-Cellular Therapies Inc. Website:
2024-06-20 15:00:05 ET Graig Suvannavejh from Mizuho Securities issued a price target of $100.00 for ITCI on 2024-06-20 12:10:00. The adjusted price target was set to $100.00. At the time of the announcement, ITCI was trading at $76.06. The overall price target consensus...
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery- Åsberg Depression Rating Sc...
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Office...